Intra-Tumoral Pharmacokinetics of Pazopanib in Combination with Radiotherapy in Patients with Non-Metastatic Soft-Tissue Sarcoma

被引:3
作者
Molenaar-Kuijsten, Laura [1 ]
van Meekeren, Milan [2 ]
Verheijen, Remy B. [1 ]
Bovee, Judith V. M. G. [3 ]
Fiocco, Marta [4 ,5 ]
Thijssen, Bas [1 ]
Rosing, Hilde [1 ]
Huitema, Alwin D. R. [1 ,6 ,7 ]
Miah, Aisha B. [8 ,9 ]
Gelderblom, Hans [2 ]
Haas, Rick L. M. [10 ,11 ]
Steeghs, Neeltje [12 ]
机构
[1] Netherlands Canc Inst Antoni van Leeuwenhoek, Dept Pharm & Pharmacol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands
[2] Leiden Univ, Med Ctr, Dept Med Oncol, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands
[3] Leiden Univ, Med Ctr, Dept Pathol, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands
[4] Leiden Univ, Math Inst, Niels Bohrweg 1, NL-2333 CA Leiden, Netherlands
[5] Leiden Univ, Med Ctr, Sect Med Stat, Dept Biomed Data Sci, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands
[6] Univ Utrecht, Univ Med Ctr Utrecht, Dept Clin Pharm, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands
[7] Princess Maxima Ctr Pediat Oncol, Dept Pharmacol, Heidelberglaan 25, NL-3584 EA Utrecht, Netherlands
[8] Royal Marsden Hosp, Dept Clin Oncol, 15 Cotswold Rd, London SM2 5NG, England
[9] Inst Canc Res, 15 Cotswold Rd, London SM2 5NG, England
[10] Netherlands Canc Inst Antoni van Leeuwenhoek, Dept Radiotherapy, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands
[11] Leiden Univ, Med Ctr, Dept Radiotherapy, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands
[12] Netherlands Canc Inst Antoni van Leeuwenhoek, Dept Med Oncol & Clin Pharmacol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands
关键词
intra-tumoral drug concentration; neoadjuvant treatment; pharmacokinetics; tyrosine kinase inhibitor; pazopanib; soft tissue sarcoma; GROWTH-FACTOR TREATMENT; VASCULAR NORMALIZATION; KINASE INHIBITORS; LUNG-CANCER; ANGIOGENESIS; OXYGENATION; RADIATION; EXPOSURE; SURVIVAL; PLASMA;
D O I
10.3390/cancers13225780
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary: Pazopanib plasma levels have been associated with treatment efficacy. Since pazopanib targets receptors present on cells in the vicinity of the tumor and on tumor cells themselves, measurement of pazopanib concentrations in tumor tissue might be an even better prognostic biomarker than plasma levels. The aim of our study was to quantify pazopanib concentrations in tumor tissue, correlate this with plasma concentrations, and assess whether this is a better biomarker for efficacy. A modest correlation was found between pazopanib tumor concentrations and plasma concentrations. Additionally, no correlation was found between pazopanib tumor concentrations and efficacy. We provide recommendations for future studies in which pazopanib concentrations are measured. There is a lack of understanding whether plasma levels of anticancer drugs (such as pazopanib) correlate with intra-tumoral levels and whether the plasma compartment is the best surrogate for pharmacokinetic and pharmacodynamic evaluation. Therefore, we aimed to quantify pazopanib concentrations in tumor tissue, to assess the correlation between tumor concentrations and plasma concentrations and between tumor concentrations and efficacy. In this clinical trial, non-metastatic STS patients were treated with neo-adjuvant concurrent radiotherapy and pazopanib. Plasma samples and tumor biopsies were collected, and pazopanib concentrations were measured using liquid chromatography-tandem mass spectrometry. Twenty-four evaluable patients were included. The median pazopanib tumor concentration was 19.2 mu g/g (range 0.149-200 mu g/g). A modest correlation was found between tumor concentrations and plasma levels of pazopanib (rho = 0.41, p = 0.049). No correlation was found between tumor concentrations and percentage of viable tumor cells (p > 0.05); however, a trend towards less viable tumor cells in patients with high pazopanib concentrations in tumor tissue was observed in a categorical analysis. Possible explanations for the lack of correlation might be heterogeneity of the tumors and timing of the biopsy procedure.
引用
收藏
页数:12
相关论文
共 34 条
  • [1] Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle
    Bartelink, Imke H.
    Jones, Ella F.
    Shahidi-Latham, Sheerin K.
    Lee, Pei Rong Evelyn
    Zheng, Yanan
    Vicini, Paolo
    van't Veer, Laura
    Wolf, Denise
    Iagaru, Andrei
    Kroetz, Deanna L.
    Prideaux, Brendan
    Cilliers, Cornelius
    Thurber, Greg M.
    Wimana, Zena
    Gebhart, Geraldine
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 106 (01) : 148 - 163
  • [2] Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation
    Batchelor, Tracy T.
    Gerstner, Elizabeth R.
    Emblem, Kyrre E.
    Duda, Dan G.
    Kalpathy-Cramer, Jayashree
    Snuderl, Matija
    Ancukiewicz, Marek
    Polaskova, Pavlina
    Pinho, Marco C.
    Jennings, Dominique
    Plotkin, Scott R.
    Chi, Andrew S.
    Eichler, April F.
    Dietrich, Jorg
    Hochberg, Fred H.
    Lu-Emerson, Christine
    Iafrate, A. John
    Ivy, S. Percy
    Rosen, Bruce R.
    Loeffler, Jay S.
    Wen, Patrick Y.
    Sorensen, A. Greg
    Jain, Rakesh K.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (47) : 19059 - 19064
  • [3] Scheduling of radiation with angiogenesis inhibitors anginex and avastin improves therapeutic outcome via vessel normalization
    Dings, Ruud P. M.
    Loren, Melissa
    Heun, Hanke
    McNiel, Elizabeth
    Griffioen, Arjan W.
    Mayo, Kevin H.
    Griffin, Robert J.
    [J]. CLINICAL CANCER RESEARCH, 2007, 13 (11) : 3395 - 3402
  • [4] European Medicines Agency Committee for Medicinal Products for Human Use (CHMP), PAZ EUR PUBL ASS REP
  • [5] Fletcher C, 2013, WHO CLASSIFICATION T, V4th
  • [6] Combining Radiotherapy With Anti-angiogenic Therapy and Immunotherapy; A Therapeutic Triad for Cancer?
    Goedegebuure, Ruben S. A.
    de Klerk, Leonie K.
    Bass, Adam J.
    Derks, Sarah
    Thijssen, Victor L. J. L.
    [J]. FRONTIERS IN IMMUNOLOGY, 2019, 9
  • [7] NORMALIZATION OF THE VASCULATURE FOR TREATMENT OF CANCER AND OTHER DISEASES
    Goel, Shom
    Duda, Dan G.
    Xu, Lei
    Munn, Lance L.
    Boucher, Yves
    Fukumura, Dai
    Jain, Rakesh K.
    [J]. PHYSIOLOGICAL REVIEWS, 2011, 91 (03) : 1071 - 1121
  • [8] A phase I study on the combination of neoadjuvant radiotherapy plus pazopanib in patients with locally advanced soft tissue sarcoma of the extremities
    Haas, Rick L. M.
    Gelderblom, Hans
    Sleijfer, Stefan
    van Boven, Hester H.
    Scholten, Astrid
    Dewit, Luc
    Borst, Gerben
    van der Hage, Jos
    Kerst, J. Martijn
    Nout, Remi A.
    Hartgrink, Henk H.
    de Pree, Ilse
    Verhoef, Cornelis
    Steeghs, Neeltje
    van Coevorden, Frits
    [J]. ACTA ONCOLOGICA, 2015, 54 (08) : 1195 - 1201
  • [9] (Pre-)Clinical Pharmacology and Activity of Pazopanib, a Novel Multikinase Angiogenesis Inhibitor
    Hamberg, Paul
    Verweij, Jaap
    Sleijfer, Stefan
    [J]. ONCOLOGIST, 2010, 15 (06) : 539 - 547
  • [10] A Pilot Study of Preoperative Gefitinib for Early-Stage Lung Cancer to Assess Intratumor Drug Concentration and Pathways Mediating Primary Resistance
    Haura, Eric B.
    Sommers, Eric
    Song, Lanxi
    Chiappori, Alberto
    Becker, Aaron
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (11) : 1806 - 1814